Clinical trials: Hemostatic Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003493
- Testing
- dexamethasone, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Sponsor
- The Cleveland Clinic
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Background: Bortezomib is a drug approved by the Food and Drug Administration (FDA) to treat patients with multiple myeloma. It is given by intravenous injection. Lenalidomide is a drug that alters the immune system.
- Trial name
- NCT01647165
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)
Waldenstroms Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
This is a Phase II multicenter study designed to evaluate the safety and efficacy of combination BDR. BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM.
- Trial name
- BDR-WM (NCT00832234)
- Testing
- Bortezomib, Dexamethasone, Rituximab
- Where
- Greece
- Volunteers
- 59 people
- Sponsor
- European Myeloma Network B.V.
Relapsed Refractory Multiple Myeloma
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
To characterize safety associated with the use of Kyprolis under the locally approved label.
- Trial name
- NCT03934684
- Testing
- Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone
- Where
- 17 sites in India
- Volunteers
- 101 people
- Sponsor
- Amgen
Multiple Myeloma
Agaricus Blazei Murill in Patients With Multiple Myeloma
Extract from the mushroom Agaricus blazei Murill har been shown to have strong immunomodulating properties both in cell cultures, animal models and in humans.
- Trial name
- NCT00970021
- Testing
- Intake of 60 ml agaricus daily in addition to chemotherapy
- Where
- Norway
- Volunteers
- 39 people
- Sponsor
- Ullevaal University Hospital
Multiple Myeloma
A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged lesion uptake of dexamethasone and therefore…
- Trial name
- AMETHYST (NCT03033316)
- Testing
- Dexamethasone
- Volunteers
- 7 people
- Sponsor
- Enceladus Pharmaceuticals BV
Epistaxis, Anterior Ethmoid Artery
Cauterization of the Anterior Ethmoidal Artery by Transconjunctival Approach
The incidence of epistaxis varies from 7 to 14% in the general population and represents 30 per 100,000 emergency room admissions in adults. Most nasal bleeding is self-limiting without the need for specific medical treatment.
- Trial name
- AEA (NCT05663099)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Ehlers Danlos Syndrome
Hypermobile Ehlers Danlos Syndrome Healthcare Usage and Outcomes in England
To understand the access to services and outcomes for patients with hypermobile Ehlers Danlos Syndrome
- Trial name
- hEDS-Out (NCT07878793)
- Sponsor
- Walton Centre NHS Foundation Trust
Multiple Myeloma
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
- Trial name
- NCT05002816
- Testing
- Elotuzumab, Belantamab mafodotin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Multiple Myeloma
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib.
- Trial name
- Myeloma XI (NCT01554852)
- Testing
- Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
- Where
- United Kingdom
- Volunteers
- 4,420 people
- Sponsor
- University of Leeds
Coagulation Defect, Snake Bites
Study Comparing Modified Lee White Clotting Time Against Twenty Minute Whole Blood Clotting Test in Snakebite Victims
20 minute Whole Blood Clotting Test(20'WBCT) recommended by World Health Organisation guidelines is probably the most routinely employed bed side screening tool in the country.
- Trial name
- LAT (NCT03890016)
- Testing
- 20'Whole Blood ClottingTest (WBCT), Modified Lee and White (MLW) Method Clotting Time
- Where
- India
- Volunteers
- 230 people
- Sponsor
- Appu Suseel
Relapsed/Refractory Multiple Myeloma
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07454187
- Testing
- SG2918
- Where
- 4 sites in China
- Volunteers
- 40 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Multiple Myeloma
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory…
- Trial name
- SCORE (NCT02628704)
- Testing
- Selinexor, carfilzomib, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Coronary Artery Disease, Coronary Angiography
HEMOSTATİC PAD AND SANDBAG
The aim of this study is to compare bleeding outcomes, pain, comfort levels, sleep quality, and associated factors among patients receiving a chitosan-based hemostatic pad versus a sandbag following femoral coronary angiography…
- Conditions
- Coronary Artery Disease, Coronary Angiography, Vascular Access Site Complications
- Trial name
- NCT07771127
- Testing
- Chitosan-Based Hemostatic Pad, Sandbag Application
- Where
- Turkey (Türkiye)
- Volunteers
- 480 people
- Sponsor
- Uludag University
Breast Cancer, Chronic Myeloproliferative Disorders
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00946283
- Testing
- Lactobacillus rhamnosus GG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Percutaneous Coronary Intervention, Hemostatic Disorder
Gyeongsang National University Hospital Registry
The G-NUH registry is a two-center, real-world registry of percutaneous coronary intervention in patients with significant coronary artery disease.
- Conditions
- Percutaneous Coronary Intervention, Hemostatic Disorder, Blood Clot
- Trial name
- GNUH (NCT04650529)
- Testing
- stent, ballooning
- Where
- 2 sites in South Korea
- Volunteers
- 10,000 people
- Sponsor
- Gyeongsang National University Hospital
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
The purpose of this study is to evaluate the efficacy and safety of salvage treatment with carfilzomib/lenalidomide/dexamethasone (KRD) followed by 2nd autologous stem cell transplantation (ASCT) and lenalidomide maintenance in…
- Trial name
- KMM1911 (NCT05497102)
- Testing
- Lenalidomide maintenance
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Samsung Medical Center
B-Cell Prolymphocytic Leukemia, Hypodiploidy
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic…
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia
- Trial name
- NCT01008462
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00060346
- Testing
- rituximab, cyclophosphamide, Doxorubicin
- Where
- 153 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.